On February 25, 2022 Privo Technologies, Inc. ("Privo", "the Company"), a clinical stage biopharmaceutical company focused on optimizing state-of-the-art oncology treatments reported that it has received $2.5M grant as part of National Cancer Institute’s Notice of Special Interest announcement (Press release, Privo Technologies, FEB 25, 2022, View Source;utm_medium=rss&utm_campaign=privo-technologies-inc-awarded-from-nci-intraoperative-treatment-solid-tumors [SID1234609064]).
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
The award supports the first-in-man clinical study of Privo’s PRV211 Intraoperative Anti-Cancer Treatment. It is used for all solid tumors to eliminate any remining cancer cells post-surgical resection. The intraoperative treatment would be applied to the tumor bed immediately following tumor resection to eliminate micrometastases and treat nearby lymph nodes. PRV211 is a sterile derivative of the PRV nanoengineered platform technology which safely and effectively deliver locoregional anticancer treatments.
"Privo Technologies is thankful for the continued support by the NCI in the development of the PRV Platform," said Manijeh Goldberg, PhD, CEO of Privo Technologies, Inc. "Privo Technologies seeks to transform the standard of care for treating solid tumors. Surgeons have a challenging balancing act – cut out too much and damage functionality, remove too little and risk leaving tumor cells behind."
The clinical trial will initially enroll patients with advanced head and neck cancer and will then recruit patients with other solid tumors. Privo plans to open enrollment for this study in 2022.